Skip to main content
ASX:CHM

Chimeric Therapeutics Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive CHM News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimeric Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Chimeric Therapeutics

Chimeric Therapeutics Limited, a biotechnology company, develops and commercializes chimeric antigen receptor T cell therapy drugs for solid tumors in Australia. It is developing CLTX-CAR T cell therapy that is Phase I clinical study in Glioblastoma. The company was incorporated in 2020 and is based in Carlton, Australia.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Stock Exchange ASX
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolASX:CHM
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.chimerictherapeutics.com
Phone61 3 9824 5254
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

MarketRank™

Overall MarketRank™

0.33 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Chimeric Therapeutics (ASX:CHM) Frequently Asked Questions

What stocks does MarketBeat like better than Chimeric Therapeutics?

Wall Street analysts have given Chimeric Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Chimeric Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Chimeric Therapeutics' key executives?

Chimeric Therapeutics' management team includes the following people:
  • Mr. Paul Edward-Alexander Hopper, Exec. Chairman (Age 65)
  • Mr. Phillip Hains C.A., M.B.A., B Bus, CA, MBA, Director & Sec. (Age 60)

Who are some of Chimeric Therapeutics' key competitors?

Some companies that are related to Chimeric Therapeutics include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF) and Almirall (LBTSF).
View all of CHM's competitors.

What is Chimeric Therapeutics' stock symbol?

Chimeric Therapeutics trades on the ASX under the ticker symbol "CHM."

How much money does Chimeric Therapeutics make?

Chimeric Therapeutics has a market capitalization of $0.00.

What is Chimeric Therapeutics' official website?

The official website for Chimeric Therapeutics is www.chimerictherapeutics.com.

How can I contact Chimeric Therapeutics?

The company can be reached via phone at 61 3 9824 5254.


This page was last updated on 5/12/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.